Get the Stockscreener App
0.3778
2.11%
0.0078
After Hours:
.37
-0.0078
-2.06%
Bluebird Bio Inc stock is traded at $0.3778, with a volume of 4.23M.
It is up +2.11% in the last 24 hours and down -21.32% over the past month.
See More
Previous Close:
$0.37
Open:
$0.369
24h Volume:
4.23M
Relative Volume:
0.66
Market Cap:
$75.10M
Revenue:
$21.73M
Net Income/Loss:
$-91.17M
P/E Ratio:
-0.3704
EPS:
-1.02
Net Cash Flow:
$-286.43M
1W Performance:
+24.69%
1M Performance:
-21.32%
6M Performance:
-60.91%
1Y Performance:
-90.16%
1-Day Range:
$0.36
$0.387
1-Week Range:
$0.29
$0.41
52-Week Range:
$0.29
$5.53
Bluebird Bio Inc Stock (BLUE) Company Profile
Name
Bluebird Bio Inc
Sector
Industry
Phone
339-499-9300
Address
455 GRAND UNION BOULEVARD, SOMERVILLE, MA
Compare BLUE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BLUE
Bluebird Bio Inc
|
0.3778 | 75.10M | 21.73M | -91.17M | -286.43M | -1.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Bluebird Bio Inc Stock (BLUE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-15-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Aug-15-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-11-23 | Downgrade | HSBC Securities | Hold → Reduce |
| Dec-08-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Oct-17-23 | Initiated | Cantor Fitzgerald | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Jul-19-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-01-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Apr-28-23 | Initiated | JP Morgan | Overweight |
| Mar-07-23 | Initiated | Robert W. Baird | Outperform |
| Aug-05-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-02-22 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Apr-06-22 | Downgrade | Cowen | Outperform → Market Perform |
| Mar-07-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Nov-08-21 | Reiterated | Barclays | Equal Weight |
| Nov-08-21 | Reiterated | Canaccord Genuity | Hold |
| Nov-08-21 | Downgrade | Goldman | Neutral → Sell |
| Nov-08-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-08-21 | Reiterated | RBC Capital Mkts | Sector Perform |
| Nov-08-21 | Reiterated | Wedbush | Neutral |
| Nov-08-21 | Reiterated | Wells Fargo | Equal Weight |
| Aug-10-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| Aug-10-21 | Downgrade | Goldman | Buy → Neutral |
| Aug-10-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-10-21 | Resumed | William Blair | Mkt Perform |
| Aug-09-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-01-21 | Downgrade | Berenberg | Buy → Hold |
| Mar-10-21 | Upgrade | Mizuho | Neutral → Buy |
| Feb-17-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-16-21 | Downgrade | BofA Securities | Buy → Neutral |
| Feb-16-21 | Downgrade | Wedbush | Outperform → Neutral |
| Feb-16-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-09-20 | Downgrade | Maxim Group | Buy → Hold |
| Nov-11-20 | Initiated | Berenberg | Buy |
| Nov-05-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Nov-05-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Nov-05-20 | Downgrade | Stifel | Buy → Hold |
| Nov-02-20 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-20-20 | Initiated | Mizuho | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| Mar-27-20 | Upgrade | Stifel | Hold → Buy |
| Feb-19-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Feb-03-20 | Resumed | BofA/Merrill | Buy |
| Feb-03-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-13-19 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Nov-19-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-04-19 | Upgrade | Wedbush | Neutral → Outperform |
| Oct-01-19 | Initiated | Stifel | Hold |
| Aug-12-19 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-18-19 | Upgrade | Maxim Group | Hold → Buy |
View All
Bluebird Bio Inc Stock (BLUE) Latest News
FDA investigating safety risks of bluebird's Skysona (NASDAQ:BLUE) - Seeking Alpha
FDA probes blood cancer risk from bluebird's gene therapy, weighs regulatory action - Reuters
bluebird bio extends selloff as BofA and J.P. Morgan cut after Q3 results - MSN
bluebird bio (NASDAQ:BLUE) Now Covered by StockNews.com - MarketBeat
bluebird bio, Inc. (NASDAQ:BLUE) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Adrenoleukodystrophy Treatment Market Global Share, Trends, - openPR
Bluebird Bio's SWOT analysis: gene therapy firm faces cash crunch amid launch - Investing.com
Bluebird Bio (BLUE) Reports Q3 Loss, Lags Revenue Estimates - MSN
bluebird bio says seeking more cash to achieve cash flow break-even - MSN
Layoff Tracker: Adaptimmune Downsizes by 33% in Strategic Realignment - BioSpace
Adoptive Cell Therapy Market Industry Insights: Market Size, - openPR
StockNews.com Begins Coverage on bluebird bio (NASDAQ:BLUE) - MarketBeat
B of A Securities Downgrades bluebird bio (BLUE) - MSN
bluebird bio Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Earnings Snapshot: bluebird bio reports mixed Q3, Q4 revenue outlook below consensus - MSN
JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options - AOL
Royal Bank of Canada Reaffirms "Sector Perform" Rating for bluebird bio (NASDAQ:BLUE) - MarketBeat
bluebird bio downgraded by Bank of America, shares tumble - Proactive Investors USA
bluebird bio stock cut at BofA and J.P. Morgan (BLUE:NASDAQ) - Seeking Alpha
Bluebird bio stock plunges to 52-week low of $0.34 By Investing.com - Investing.com Canada
Barclays Lowers bluebird bio (NASDAQ:BLUE) Price Target to $2.00 - MarketBeat
Bluebird bio stock plunges to 52-week low of $0.34 - Investing.com
bluebird bio (NASDAQ:BLUE) Cut to "Neutral" at Bank of America - MarketBeat
bluebird bio (NASDAQ:BLUE) Lowered to Underweight Rating by JPMorgan Chase & Co. - MarketBeat
bluebird bio, Inc. (NASDAQ:BLUE) Q3 2024 Earnings Call Transcript - Insider Monkey
bluebird bio, Inc.'s (NASDAQ:BLUE) Revenues Are Not Doing Enough For Some Investors - Simply Wall St
Bluebird: Q3 Earnings Snapshot - Darien Times
bluebird bio Inc (BLUE) Q3 2024 Earnings Call Highlights: Naviga - GuruFocus.com
bluebird bio Inc (BLUE) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges and ... - Yahoo Finance
Bluebird bio Reports Q3 2024 Earnings and Future Outlook - TipRanks
bluebird bio Inc (BLUE) Quarterly 10-Q Report - Quartzy
Earnings call: Bluebird bio sees patient growth, aims for 2025 breakeven - Investing.com
bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance - citybiz
Bluebird bio says it needs cash to operate beyond March 2025 - The Business Journals
Cell and Gene Therapy Market to Grow by USD 6.56 Billion (2024-2028), Driven by Rising Prevalence of Chronic Diseases, AI-Powered Report Explores Market EvolutionTechnavio - The Malaysian Reserve
BLUE (bluebird bio) Price-to-Operating-Cash-Flow : (As of Nov. 14, 2024) - GuruFocus.com
Q3 2024 bluebird bio Inc Earnings Call Transcript - GuruFocus.com
Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size, - openPR
bluebird bio Q3 2024 Earnings Preview - MSN
Goldman Sachs Group Inc's Strategic Acquisition of Shares in blu - GuruFocus.com
Gene Therapy For Rare Disease Market Growth Demand, Segment - openPR
Eagle Pharmaceuticals Taps Former Bluebird Bio CFO Krawtschuk to Lead Finance | EGRX Stock News - StockTitan
bluebird bio (NASDAQ:BLUE) Earns Sell Rating from Analysts at StockNews.com - MarketBeat
bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter 2024 Results Call - BioSpace
bluebird bio expands incentive plan amid leadership changes - Investing.com India
Bluebird Bio’s Key Decisions and Shareholder Engagement in 2024 - TipRanks
bluebird bio expands incentive plan amid leadership changes By Investing.com - Investing.com UK
bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results Call - Business Wire
What's Going On With Bluebird Bio Stock? - MSN
bluebird bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition - BioSpace
Bluebird bio stock plunges to 52-week low of $0.45 amid downturn - Investing.com Australia
Bluebird Bio Inc Stock (BLUE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):